not only by the target bacterial cells but possibly also by other pathogenic bacteria. Furthermore, conventional, systemic antibiotic treatment can interact with other drugs, including contraceptive pills. Certain antibiotics cannot be combined with the use of alcohol. Accordingly, there is a need for improved treatment of eczema.

Summary

In one aspect, there is provided a composition comprising a first and a second compound, wherein said first compound is an anti-inflammatory compound selected from the group consisting of a corticosteroid, a calcineurin inhibitor, an immunotherapeutic compound, a recombinant human IFN-gamma, a microbial probiotic, a cytokine modulator, an inflammatory cell recruitment blocker, and a T cell activation inhibitor and said second compound is a compound specifically targeting a bacterial cell, and wherein said second compound comprises;

- at least one cell wall binding domain specifically binding the peptidoglycan cell wall of said bacterial cell; and

- one or more enzymatic active domains exhibiting target bond specificity.

In another aspect there is provided a kit of parts comprising: a) a first vial containing a first mixture comprising a first compound as defined herein; and b) a second vial containing a second mixture comprising a second compound as defined herein; and optionally, c) instructions for use.

In an embodiment, there is provided a composition as defined herein and/or a kit of parts as defined herein, for use as a medicament, comprising the administration of the composition and/or the sequential or simultaneous administration of a first and second compound of a kit of parts as disclosed above.

In another aspect, there is provided the use of a composition as defined herein and/or a kit of parts as defined herein in the manufacture of a medicament, for preventing, delaying and/or curing of dermatitis or eczema.

Claims

1. A composition comprising a first and a second compound, wherein said first compound is an anti-inflammatory compound selected from the group consisting of a corticosteroid, a calcineurin inhibitor, an immunotherapeutic compound, a recombinant human IFN-gamma, a microbial probiotic, a cytokine modulator, an inflammatory cell recruitment blocker, and a T cell activation inhibitor and said second compound is a compound specifically targeting a bacterial cell, and wherein said second compound comprises;

- at least one cell wall binding domain specifically binding the peptidoglycan cell wall of said bacterial cell; and
- one or more enzymatic active domains exhibiting target bond specificity.

2. A composition according to claim 1, wherein the second compound is specifically targeting a gram positive bacterial cell.

3. A kit of parts comprising:

a) a first vial containing a first mixture comprising a first compound as defined in claim 1; and,

b) a second vial containing a second mixture comprising a second compound as defined in claim 1 or 2; and optionally,

c) instructions for use.

4. A kit of parts according to claim 3, wherein the instructions for use comprise a dosage regime.

5. Use of a composition according to claim 1 or 2 and/or a kit of parts according to claim 3 or 4, in the manufacture of a medicament for preventing, delaying and/or curing of dermatitis or eczema.

6. A composition and/or kit of parts according to claim 5, wherein said target bond is an essential bond in a peptidoglycan layer of said bacterial cell.

7. A composition and/or kit of parts according to claim 6, wherein said bacterial cell is a gram positive bacterial cell.

8. A composition and/or kit of parts according to any one of claims 6 to 7, wherein said one or more enzymatic active domains is selected from or is a combination of a domain of the group consisting of a cysteine, histidine dependent amidohydrolases/peptidase domain, an endopeptidase domain, an amidase domain and a glycosylhydrolase domain.

9 . A composition and/or kit of parts according to any of the preceding claims, wherein said bacterial cell is a gram positive bacterial cell.

10. A composition and/or kit of parts according to claim 9, wherein said gram positive bacterial cell is a *Staphylococcus*.

11. A composition and/or kit of parts according to claim 9 or 10, wherein said cell wall binding domain originates from or is a homologue of a *Staphylococcus* phage endolysin and/or an *S. simulans* lysostaphin and/or an *S. capitis* ALE-1 bacteriocin.

12. A composition and/or kit of parts according to any one of claims 9 to 11, wherein said second compound is a polypeptide that has at least 80% identity with SEQ ID NO: SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 98 or 100; and/or said cell wall binding domain has at least 80% identity to any of SEQ ID NO: 4, 6 or 8; and/or wherein said one or more enzymatic active domains has at least 80% identity to any of SEQ ID NO: 10, 12, 14, 16, 18, 98 or 100.

13. A composition and/or kit of parts according to any of the preceding claims, wherein said second compound is a naturally occurring or mutant bacteriophage, a naturally occurring endolysin or a mutant polypeptide.

14. A composition and/or kit of parts according to any one of claims 9 to 13, wherein said second compound is a recombinant polypeptide comprising a multiplicity of one or more enzymatic active domains exhibiting target bond specificity.